Zoetis Inc. (NYSE:ZTS) Shares Sold by Addison Advisors LLC

Addison Advisors LLC cut its stake in Zoetis Inc. (NYSE:ZTS) by 8.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,195 shares of the company’s stock after selling 104 shares during the period. Addison Advisors LLC’s holdings in Zoetis were worth $195,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. AMF Tjanstepension AB grew its stake in Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after purchasing an additional 20,001 shares in the last quarter. Howard Capital Management Group LLC lifted its holdings in Zoetis by 0.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after buying an additional 883 shares during the last quarter. Arkadios Wealth Advisors grew its position in shares of Zoetis by 2.5% in the 3rd quarter. Arkadios Wealth Advisors now owns 5,045 shares of the company’s stock worth $986,000 after acquiring an additional 121 shares in the last quarter. Pallas Capital Advisors LLC grew its position in shares of Zoetis by 6.0% in the 3rd quarter. Pallas Capital Advisors LLC now owns 7,934 shares of the company’s stock worth $1,440,000 after acquiring an additional 451 shares in the last quarter. Finally, SFE Investment Counsel increased its holdings in shares of Zoetis by 1.9% in the 3rd quarter. SFE Investment Counsel now owns 27,461 shares of the company’s stock valued at $5,365,000 after acquiring an additional 514 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on ZTS. StockNews.com cut Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. Finally, Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $215.40.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.16% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $168.60 on Wednesday. The company has a 50-day moving average price of $166.26 and a two-hundred day moving average price of $177.66. The stock has a market cap of $75.50 billion, a price-to-earnings ratio of 30.82, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.